Jacek Mackiewicz

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John M. Kirkwood, Michele Del Vecchio, Jeffrey S. Weber et al. · Nature Medicine · 2023 · 174 citations · Full text

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Dalil Hannani, Marie Vétizou, David Enot et al. · Cell Research · 2015 · 157 citations · Full text

Cancer Immunosurveillance, Autoimmune Disease, Soluble Cd25 +11

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Georgina V. Long, Jason J. Luke, Muhammad A. Khattak et al. · The Lancet Oncology · 2022 · 140 citations

Surgical Oncology, Pembrolizumab Versus Placebo, Medicine +9

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Helen Gogas, Brigitte Dréno, James Larkin et al. · Annals of Oncology · 2020 · 97 citations

Brafv600 Wild-type Melanoma, Primary Results, Medicine +9

Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study

Jason J. Luke, Paolo A. Ascierto, Muhammad A. Khattak et al. · Journal of Clinical Oncology · 2024 · 84 citations · Full text